Miach Orthopaedics, Inc., a Boston, Massachusetts-based company dedicated to developing bio-engineered surgical implants for connective tissue repair, raised $22.5m in Series A financing.
The round was co-led by Amzak Health Investors LLC and DSM Venturing with participation from the NFL Players Association and additional investors.
The company intends to use the funds for accelerating manufacturing capabilities and to continue U.S. clinical trials of its first implant.
Miach Orthopaedics is dedicated to developing bio-engineered surgical implants for connective tissue repair. The company’s initial focus is on the Bridge-Enhanced® ACL Repair (BEAR®) technology as a viable alternative to conventional ACL reconstruction for patients who have sustained an anterior cruciate ligament (ACL) injury. The BEAR technology – pioneered by Martha Murray, M.D., at the Boston Children’s Hospital Department of Orthopaedic Surgery with initial research funding provided by the NFL Players Association, Boston Children’s Hospital and the National Institutes of Health – is a proprietary bio-engineered sponge used as a bridging scaffold to stimulate healing of the torn ACL.
The technology has been tested in nearly 100 human patients under Food and Drug Administration Investigational Device Exemption (IDE) in the BEAR studies.
FinSMEs
17/09/2018